Constantin Meyer - STADA Arzneimittel Insider

STDAF -- USA Stock  

USD 94.05  0.000003  0.00%

Member of the Supervisory Board

Mr. Constantin Meyer was Member of the Supervisory Board of STADA Arzneimittel AG from 2003 to August 26 2016. Since 1974 He was Chairman of the Examination Board for Pharmaceutical Technicians and Assistants of the Lower Saxon Chamber of Pharmacists. He has previously worked as a control manager and pharmaceutical advisor. From 1986 to 1992 he was responsible for the growth of MEDICA MEYER until its merger with Phabil Bielefeld. In 1986 he became Chairman of the Advisory Board of STADA Arzneimittel AG. He studied pharmacy at LudwigsUniversitaet zu Freiburg in Breisgau Germany and gained his pharmaceutical licence in 1971.
Age: 72  Executive Since 2003      
49 6101 603 0  http://www.stada.de

Management Efficiency

The company has return on total asset (ROA) of 5.45 % which means that it generated profit of $5.45 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 9.23 % meaning that it generated $9.23 on every $100 dollars invested by stockholders.
The company has accumulated 1.62 B in total debt with debt to equity ratio (D/E) of 130.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. STADA Arzneimittel Aktiengesellschaft has Current Ratio of 0.64 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.

Similar Executives

Entity Summary

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare Holding GmbH. STADA Arzneimittel operates under Drug Manufacturers - Specialty Generic classification in USA and traded on OTC Market. It employs 10176 people.STADA Arzneimittel Aktiengesellschaft (STDAF) is traded on OTC Market in USA. It is located in Stadastrasse 2-18 and employs 10,176 people.

STADA Arzneimittel A Leadership Team

Carl Oetker, Executive
JanNicolas Garbe, Executive
Dieter Koch, Executive
Eckhard Brueggemann, Executive, Ph.D
Mark Keatley, CFO
Ralph Grobecker, Managing Director, Ph.D
Martin Abend, Chairman, Ph.D
Matthias Wiedenfels, Executive, Ph.D
Arnold Hertzsch, Executive, Ph.D
Halil Duru, Executive
Tina Mueller, Executive
Engelbert Willink, Chairman
Barthold Piening, Executive, Ph.D
Helmut Kraft, CFO
Ute Pantke, Executive, Ph.D
Carsten Cron, Executive
Hartmut Retzlaff, Chairman
Bernhard Duettmann, CFO
Miguel Pagan, Executive
Claudio Albrecht, Chairman, Ph.D
Michael Siefke, Executive
Leslie Iltgen, President
Eric Cornut, Executive
Robert Knerr, Executive
Jens Steegers, Executive
Birgit Kudlek, Executive, Ph.D
Guenter Au, Chairman, Ph.D
Constantin Meyer, Executive
Rolf Hoffmann, Executive, MBA
Markus Metzger, Director
Benjamin Kunstler, Executive
Gunnar Riemann, Executive, Ph.D
Bruno Schick, Executive

Stock Performance Indicators

Current Sentiment - STDAF

STADA Arzneimittel A Investor Sentiment
Macroaxis portfolio users are evenly split in their outlook on investing in STADA Arzneimittel Aktiengesellschaft. What is your outlook on investing in STADA Arzneimittel Aktiengesellschaft? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Trending Equities

Currently Active Assets on Macroaxis
OZL   
Purchased over 100 shares of
over a week ago
Traded for 10.44
FBU   
Purchased over 300 shares of
over a week ago
Traded for 6.24
JBH   
Purchased over 70 shares of
over a week ago
Traded for 23.42
GNC   
Purchased over 200 shares of
over a week ago
Traded for 8.1
SBM   
Purchased over 400 shares of
over a week ago
Traded for 4.74
Also please take a look at World Market Map. Please also try Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..